Massachusetts Financial Services CO Tcr2 Therapeutics Inc. Transaction History

Massachusetts Financial Services CO

  • $321 Billion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 13, 2021
SELL
$20.38 - $34.07 $459,100 - $767,494
-22,527 Closed
0 $0
Q4 2020

Feb 12, 2021
SELL
$19.0 - $32.63 $4,332 - $7,439
-228 Reduced 1.0%
22,527 $697,000
Q3 2020

Nov 12, 2020
BUY
$13.1 - $20.69 $298,090 - $470,800
22,755 New
22,755 $462,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Massachusetts Financial Services CO Portfolio

Follow Massachusetts Financial Services CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email